Last updated: March 2026
Research Overview
Our research focuses on genomic and molecular phenotyping of lung diseases, especially asthma and COPD. We aim to define distinct molecular sub-phenotypes that drive disease mechanisms and response to therapy.
I. Identifying Molecular Sub-Phenotypes of Asthma and COPD
- Asthma research is supported by an NIH/NHLBI R01 grant, Molecular Phenotyping of Asthma (R01 HL-095372). This project applies high-throughput genomic analysis of airway samples to distinguish Th2-driven and non-Th2-driven asthma sub-phenotypes, which differ in clinical, pathological, and treatment characteristics.
- COPD research builds on these approaches through a seven-year NIH contract as part of the NHLBI SPIROMICS Project (N01 HR-08-08). This multi-center effort uses genomic and biomarker-based methods to identify molecular phenotypes of COPD and to develop intermediate outcome measures for clinical trials.
II. Mechanisms of Airway Inflammation and Remodeling
We study the cellular and molecular mechanisms of airway inflammation and remodeling using genomic and imaging-based approaches. Human lung tissue samples obtained via fiberoptic bronchoscopy are analyzed to uncover how structural and molecular changes contribute to asthma, COPD, and sarcoidosis.
Supported by NIH grant R01 HL-095372, our team integrates gene expression profiling (microarrays, qPCR, laser capture microdissection) with design-based stereology for quantitative assessment of airway remodeling in human samples.
III. Genomic Development of Blood-Based Diagnostics
We are developing non-invasive diagnostic tests for lung disease using blood-based genomic and miRNA profiling. By analyzing expression signatures in blood cells, plasma, and serum from individuals with asthma, COPD, and sarcoidosis, we aim to identify circulating biomarkers that can improve early detection, classification, and monitoring of disease activity.
IV. Clinical Trial Support and Translational Studies
The Woodruff Laboratory provides specialized support for clinical trials in asthma and COPD, including NIH- and industry-sponsored studies. Our work includes detailed sample analysis, measurement of airway remodeling and inflammation, and application of molecular biomarkers to interpret treatment responses.